- Home
- GDS vs CPRX Comparison
GDS vs CPRX Comparison
Compare GDS & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDS
- CPRX
- Stock Information
- Founded
- GDS 2001
- CPRX 2002
- Country
- GDS China
- CPRX United States
- Employees
- GDS N/A
- CPRX N/A
- Industry
- GDS Computer Software: Programming Data Processing
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- GDS Technology
- CPRX Health Care
- Exchange
- GDS Nasdaq
- CPRX Nasdaq
- Market Cap
- GDS 3.2B
- CPRX 1.9B
- IPO Year
- GDS 2016
- CPRX 2006
- Fundamental
- Price
- GDS $16.23
- CPRX $20.22
- Analyst Decision
- GDS Strong Buy
- CPRX Strong Buy
- Analyst Count
- GDS 4
- CPRX 6
- Target Price
- GDS $15.29
- CPRX $29.50
- AVG Volume (30 Days)
- GDS 2.1M
- CPRX 867.1K
- Earning Date
- GDS 08-21-2024
- CPRX 11-06-2024
- Dividend Yield
- GDS N/A
- CPRX N/A
- EPS Growth
- GDS N/A
- CPRX N/A
- EPS
- GDS N/A
- CPRX 0.58
- Revenue
- GDS $1,448,934,069.00
- CPRX $434,475,000.00
- Revenue This Year
- GDS $17.70
- CPRX $21.33
- Revenue Next Year
- GDS $15.33
- CPRX $17.29
- P/E Ratio
- GDS N/A
- CPRX $34.83
- Revenue Growth
- GDS 9.08
- CPRX 43.42
- 52 Week Low
- GDS $5.01
- CPRX $11.55
- 52 Week High
- GDS $18.14
- CPRX $20.87
- Technical
- Relative Strength Index (RSI)
- GDS 57.05
- CPRX 60.73
- Support Level
- GDS $16.16
- CPRX $19.00
- Resistance Level
- GDS $17.74
- CPRX $20.70
- Average True Range (ATR)
- GDS 0.75
- CPRX 0.55
- MACD
- GDS -0.24
- CPRX -0.13
- Stochastic Oscillator
- GDS 5.75
- CPRX 74.12
About GDS GDS Holdings Limited ADS
GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. It has aggressively raised capital over the past four years for expansion. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.